PPAR modulation of kinase-linked receptor signaling in physiology and disease

Physiology

Volumn 25, Issue 3, 2010, Pages 176-185

  Rotman, Nicolas ^a   Wahli, Walter ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHOTRANSFERASE;

CELL DIFFERENTIATION; CELL PROLIFERATION; GENERAL ASPECTS OF DISEASE; HUMAN; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; DISEASES;

CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE; HUMANS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PHOSPHOTRANSFERASES; SIGNAL TRANSDUCTION;

EID: 77955536994     PISSN: 15489213     EISSN: 15489221     Source Type: Journal    
DOI: 10.1152/physiol.00018.2010     Document Type: Review

References (70)

1. Banfi C, Auwerx J, Poma F, Tremoli E, Mussoni L. Induction of plasminogen activator inhibitor I by the PPARalpha ligand, Wy-14,643, is dependent on ERK1/2 signalling pathway. Thromb Haemost 90: 611-619, 2003.
2. Burgermeister E, Seger R. MAPK kinases as nucleo-cytoplasmic shuttles for PPARgamma. Cell Cycle 6: 1539-1548, 2007.
3. Burns KA, Vanden Heuvel JP. Modulation of PPAR activity via phosphorylation. Biochim Biophys Acta 1771: 952-960, 2007.
4. Carpenter G, Liao HJ. Trafficking of receptor tyrosine kinases to the nucleus. Exp Cell Res 315: 1556-1566, 2009.
5. Cheng HC, Ho TC, Chen SL, Lai HY, Hong KF, Tsao YP. Troglitazone suppresses transforming growth factor betamediated fibrogenesis in retinal pigment epithelial cells. Mol Vision 14: 95-104, 2008.
6. Cho N, Momose Y. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress. Curr Topics Med Chem 8: 1483-1507, 2008.
7. Chong HC, Tan MJ, Philippe V, Tan SH, Tan CK, Ku CW, Goh YY, Wahli W, Michalik L, Tan NS. Regulation of epithelialmesenchymal IL-1 signalling by PPARbeta/delta is essential for skin homeostasis and wound healing. J Cell Biol 184: 817-831, 2009.
8. Christodoulides C, Dyson P, Sprecher D, Tsintzas K, Karpe F. Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. J Clin Endocrinol Metab 94: 3594-3601, 2009.
9. Degenhardt T, Matilainen M, Herzig KH, Dunlop TW, Carlberg C. The insulin-like growth factor-binding protein 1 gene is a primary target of peroxisome proliferator-activated receptors. J Biol Chem 281: 39607-39619, 2006.
10. Desvergne B, Michalik L, Wahli W. Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol Endocrinol 18: 1321-1332, 2004.
11. Di-Poi N, Tan NS, Michalik L, Wahli W, Desvergne B. Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signalling pathway. Mol Cell 10: 721-733, 2002.
12. Diaz-Delfin J, Morales M, Caelles C. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway. Diabetes 56: 1865-1871, 2007.
13. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68: 879-887, 1992.
14. Fauconnet S, Lascombe I, Chabannes E, Adessi GL, Desvergne B, Wahli W, Bittard H. Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J Biol Chem 277: 23534-23543, 2002.
15. Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W. From molecular action to physiological outputs: peroxisome proliferator- activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 45: 120-159, 2006.
16. Fu M, Zhang J, Zhu X, Myles DE, Willson TM, Liu X, Chen YE. Peroxisome proliferator-activated receptor gamma inhibits transforming growth factor beta-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3. J Biol Chem 276: 45888-45894, 2001.
17. Gardner OS, Dewar BJ, Earp HS, Samet JM, Graves LM. Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signalling on epidermal growth factor receptor transactivation. J Biol Chem 278: 46261-46269, 2003.
18. Gelman L, Michalik L, Desvergne B, Wahli W. Kinase signalling cascades that modulate peroxisome proliferatoractivated receptors. Curr Opin Cell Biol 17: 216-222, 2005.
19. Ghosh AK, Bhattacharyya S, Lakos G, Chen SJ, Mori Y, Varga J. Disruption of transforming growth factor beta signalling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum 50: 1305-1318, 2004.
20. Ghosh AK, Bhattacharyya S, Wei J, Kim S, Barak Y, Mori Y, Varga J. Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J 23: 2968-2977, 2009.
21. Ghosh AK, Wei J, Wu M, Varga J. Constitutive Smad signalling and Smad-dependent collagen gene expression in mouse embryonic fibroblasts lacking peroxisome proliferatoractivated receptor-gamma. Biochem Biophys Res Commun 374: 231-236, 2008.
22. Ghosh SS, Gehr TW, Ghosh S, Fakhry I, Sica DA, Lyall V, Schoolwerth AC. PPARgamma ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase. Kidney Int 64: 52-62, 2003.
23. Gressner OA, Lahme B, Rehbein K, Siluschek M, Weiskirchen R, Gressner AM. Pharmacological application of caffeine inhibits TGF-beta-stimulated connective tissue growth factor expression in hepatocytes via PPARgamma and SMAD2/3- dependent pathways. J Hepatol 49: 758-767, 2008.
24. Guo B, Koya D, Isono M, Sugimoto T, Kashiwagi A, Haneda M. Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells. Diabetes 53: 200-208, 2004.
25. Han C, Demetris AJ, Liu Y, Shelhamer JH, Wu T. Transforming growth factor-beta (TGF-beta) activates cytosolic phospholipase A2alpha (cPLA2alpha)-mediated prostaglandin E2 (PGE)2/EP1 and peroxisome proliferator-activated receptorgamma (PPAR-gamma)/Smad signalling pathways in human liver cancer cells. A novel mechanism for subversion of TGFbeta- induced mitoinhibition. J Biol Chem 279: 44344-44354, 2004.
26. Han S, Sun X, Ritzenthaler JD, Roman J. Fish oil inhibits human lung carcinoma cell growth by suppressing integrinlinked kinase. Mol Cancer Res 7: 108-117, 2009.
27. Hellemans K, Michalik L, Dittie A, Knorr A, Rombouts K, De Jong J, Heirman C, Quartier E, Schuit F, Wahli W, Geerts A. Peroxisome proliferator-activated receptor-beta signalling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology 124: 184-201, 2003.
28. Ho TC, Chen SL, Yang YC, Chen CY, Feng FP, Hsieh JW, Cheng HC, Tsao YP. 15-Deoxy-delta(12,14)-prostaglandin J2 induces vascular endothelial cell apoptosis through the sequential activation of MAPKS and p53. J Biol Chem 283: 30273-30288, 2008.
29. Huang WC, Chio CC, Chi KH, Wu HM, Lin WW. Superoxide anion-dependent Raf/MEK/ERK activation by peroxisome proliferator activated receptor gamma agonists 15-deoxydelta( 12,14)-prostaglandin J(2), ciglitazone, and GW1929. Exp Cell Res 277: 192-200, 2002.
30. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, Li Y, Goetz R, Mohammadi M, Esser V, Elmquist JK, Gerard RD, Burgess SC, Hammer RE, Mangelsdorf DJ, Kliewer SA. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 5: 415-425, 2007.
31. Irukayama-Tomobe Y, Miyauchi T, Sakai S, Kasuya Y, Ogata T, Takanashi M, Iemitsu M, Sudo T, Goto K, Yamaguchi I. Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway. Circulation 109: 904-910, 2004.
32. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645-650, 1990.
33. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 103: 1489-1498, 1999.
34. Kim DJ, Murray IA, Burns AM, Gonzalez FJ, Perdew GH, Peters JM. Peroxisome proliferator-activated receptor-beta/delta inhibits epidermal cell proliferation by down-regulation of kinase activity. J Biol Chem 280: 9519-9527, 2005.
35. Kim HJ, Ham SA, Kim SU, Hwang JY, Kim JH, Chang KC, Yabe-Nishimura C, Kim JH, Seo HG. Transforming growth factor-beta1 is a molecular target for the peroxisome proliferator-activated receptor delta. Circ Res 102: 193-200, 2008.
36. Kim HJ, Kim MY, Jin H, Kim HJ, Kang SS, Kim HJ, Lee JH, Chang KC, Hwang JY, Yabe-Nishimura C, Kim JH, Seo HG. Peroxisome proliferator-activated receptor delta regulates extracellular matrix and apoptosis of vascular smooth muscle cells through the activation of transforming growth factor-beta1/Smad3. Circ Res 105: 16-24, 2009.
37. Kim KH, Cho YS, Park JM, Yoon SO, Kim KW, Chung AS. Pro-MMP-2 activation by the PPARgamma agonist, ciglitazone, induces cell invasion through the generation of ROS and the activation of ERK. FEBS Lett 581: 3303-3310, 2007.
38. Kintscher U, Lyon C, Wakino S, Bruemmer D, Feng X, Goetze S, Graf K, Moustakas A, Staels B, Fleck E, Hsueh WA, Law RE. PPARalpha inhibits TGF-beta-induced beta5 integrin transcription in vascular smooth muscle cells by interacting with Smad4. Circ Res 91: e35-e443303-3310, 2002.
39. Kramer DK, Al-Khalili L, Guigas B, Leng Y, Garcia- Roves PM, Krook A. Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle. J Biol Chem 282: 19313-19320, 2007.
40. Lee JH, Woo JH, Woo SU, Kim KS, Park SM, Joe EH, Jou I. The 15-deoxy-delta 12,14-prostaglandin J2 suppresses monocyte chemoattractant protein-1 expression in IFN-gamma-stimulated astrocytes through induction of MAPK phosphatase-1. J Immunol 181: 8642-8649, 2008.
41. 2signalling pathway. J Cell Biochem 106: 823-834, 2009.
42. Li M, Lee TW, Yim AP, Mok TS, Chen GG. Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-gamma- and ERKdependent in human non-small lung cancer cells. J Cell Physiol 209: 428-438, 2006.
43. Li Y, Wen X, Spataro BC, Hu K, Dai C, Liu Y. Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists. J Am Soc Nephrol 17: 54-65, 2006.
44. Lin J, Chen A. Activation of peroxisome proliferatoractivated receptor-gamma by curcumin blocks the signalling pathways for PDGF and EGF in hepatic stellate cells. Lab Invest 88: 529-540, 2008.
45. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L, Hung MC. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nature Cell Biol 3: 802-808, 2001.
46. Lombardi A, Cantini G, Piscitelli E, Gelmini S, Francalanci M, Mello T, Ceni E, Varano G, Forti G, Rotondi M, Galli A, Serio M, Luconi M. A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-alpha and interferon-gamma inflammatory effects in human endothelial cells. Arterioscler Thromb Vasc Biol 28: 718-724, 2008.
47. Massague J, Blain SW, Lo RS. TGFbeta signalling in growth control, cancer, and heritable disorders. Cell 103: 295-309, 2000.
48. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 58: 726-741, 2006.
49. Michalik L, Desvergne B, Wahli W. Peroxisomeproliferator- activated receptors and cancers: complex stories. Nature Rev 4: 61-70, 2004.
50. Michalik L, Wahli W. PPARs mediate lipid signalling in inflammation and cancer. PPAR Res 2008: 134059, 2008.
51. Park JY, Bae MA, Cheon HG, Kim SS, Hong JM, Kim TH, Choi JY, Kim SH, Lim J, Choi CH, Shin HI, Kim SY, Park EK. A novel PPARgamma agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways. Biochem Biophys Res Commun 378: 645-649, 2009.
52. Poleni PE, Bianchi A, Etienne S, Koufany M, Sebillaud S, Netter P, Terlain B, Jouzeau JY. Agonists of peroxisome proliferators-activated receptors (PPAR) alpha, beta/delta or gamma reduce transforming growth factor (TGF)-beta-induced proteoglycans' production in chondrocytes. Osteoarthritis Cartilage 15: 493-505, 2007.
53. Reitman ML. FGF21: a missing link in the biology of fasting. Cell Metab 5: 405-407, 2007.
54. Rodriguez-Calvo R, Serrano L, Coll T, Moullan N, Sanchez RM, Merlos M, Palomer X, Laguna JC, Michalik L, Wahli W, Vazquez-Carrera M. Activation of peroxisome proliferator-activated receptor beta/ delta inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signalrelated kinase 1/2. Diabetes 57: 2149-2157, 2008.
55. Romanowska M, al Yacoub N, Seidel H, Donandt S, Gerken H, Phillip S, Haritonova N, Artuc M, Schweiger S, Sterry W, Foerster J. PPARdelta enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor. J Invest Dermatol 128: 110-124, 2008.
56. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 340: 115-126, 1999.
57. Rotman N, Wahli W. Fatty acid synthesis and PPARalpha hand in hand. Chem Biol 16: 801-802, 2009.
58. Ruiz E, Redondo S, Gordillo-Moscoso A, Tejerina T. Pioglitazone induces apoptosis in human vascular smooth muscle cells from diabetic patients involving the transforming growth factor-beta/ activin receptor-like kinase-4/5/7/Smad2 signalling pathway. J Pharmacol Exp Therap 321: 431-438, 2007.
59. Schiefelbein D, Seitz O, Goren I, Dissmann JP, Schmidt H, Bachmann M, Sader R, Geisslinger G, Pfeilschifter J, Frank S. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair. Mol Pharmacol 74: 952-963, 2008.
60. Schlessinger J. Cell signalling by receptor tyrosine kinases. Cell 103: 211-225, 2000.
61. Tan NS, Michalik L, Di-Poi N, Ng CY, Mermod N, Roberts AB, Desvergne B, Wahli W. Essential role of Smad3 in the inhibition of inflammation-induced PPARbeta/delta expression. EMBO J 23: 4211-4221, 2004.
62. Takahashi H, Fujita K, Fujisawa T, Yonemitsu K, Tomimoto A, Ikeda I, Yoneda M, Masuda T, Schaefer K, Saubermann LJ, Shimamura T, Saitoh S, Tachibana M, Wada K, Nakagama H, Nakajima A. Inhibition of peroxisome proliferator- activated receptor gamma activity in esophageal carcinoma cells results in a drastic decrease of invasive properties. Cancer Sci 97: 854-860, 2006.
63. Tencer L, Burgermeister E, Ebert MP, Liscovitch M. Rosiglitazone induces caveolin-1 by PPARgammadependent and PPRE-independent mechanisms: the role of EGF receptor signalling and its effect on cancer cell drug resistance. Anticancer Res 28: 895-906, 2008.
64. Wada K, Nakajima A, Katayama K, Kudo C, Shibuya A, Kubota N, Terauchi Y, Tachibana M, Miyoshi H, Kamisaki Y, Mayumi T, Kadowaki T, Blumberg RS. Peroxisome proliferator-activated receptor gamma-mediated regulation of neural stem cell proliferation and differentiation. J Biol Chem 281: 12673-12681, 2006.
65. Wang D, Wang H, Guo Y, Ning W, Katkuri S, Wahli W, Desvergne B, Dey SK, DuBois RN. Crosstalk between peroxisome proliferatoractivated receptor delta and VEGF stimulates cancer progression. Proc Natl Acad Sci USA 103: 19069-19074, 2006.
66. Wang H, Qiang L, Farmer SR. Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Mol Cell Biol 28: 188-200, 2008.
67. Wheeler MD, Smutney OM, Check JF, Rusyn I, Schulte-Hermann R, Thurman RG. Impaired Ras membrane association and activation in PPARalpha knockout mice after partial hepatectomy. Am J Physiol Gastrointest Liver Physiol 284: G302-G312, 2003.
68. Yamaguchi K, Cekanova M, McEntee MF, Yoon JH, Fischer SM, Renes IB, Van Seuningen I, Baek SJ. Peroxisome proliferator-activated receptor ligand MCC-555 suppresses intestinal polyps in ApcMin/mice via extracellular signal-regulated kinase and peroxisome proliferator-activated receptor- dependent pathways. Mol Cancer Therap 7: 2779-2787, 2008.
69. Yin Y, Yuan H, Zeng X, Kopelovich L, Glazer RI. Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptordependent tumor specification. Cancer Res 69: 687-694, 2009.
70. Zhang GY, Cheng T, Zheng MH, Yi CG, Pan H, Li ZJ, Chen XL, Yu Q, Jiang LF, Zhou FY, Li XY, Yang JQ, Chu TG, Gao WY. Activation of peroxisome proliferator-activated receptor-gamma inhibits transforming growth factor-beta1 induction of connective tissue growth factor and extracellular matrix in hypertrophic scar fibroblasts in vitro. Arch Dermatol Res 301: 515-522, 2009.